Evidence map›Paper›PMID 40473464›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Imaging Efficacy of [

Stefano Fanti, Javier Jesus Robles Barba, Spencer Behr, Tobias Maurer, Pilar Paredes, Jochen Walz, Joan Duch, Marc Simo Perdigo, Ismini Charis Mainta, Pierre Benoit Bonnefoy and 7 more

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04838613 (Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04838613 phase3completednot on this map

Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]

TypeinterventionalSponsorNovartis PharmaceuticalsRan2021 to 2023Enrolled190ConditionsProstatic Neoplasms, Prostate Cancer, RecurrenceArms[18F]CTT1057, [68Ga]Ga-PSMA-11
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Stefano FantiNuclear Medicine, IRCCS AOU di Bologna, Bologna, Italy; stefano.fanti@aosp.bo.it.
Javier Jesus Robles BarbaNuclear Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Spencer BehrUniversity of California San Francisco, San Francisco, California.
Tobias MaurerDepartment of Urology and Martini-Klinik Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany.
Pilar ParedesClinic Hospital Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Jochen WalzDepartment of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
Joan DuchHospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Marc Simo PerdigoHospital Universitari Vall d'Hebron, Barcelona, Spain.
Ismini Charis MaintaDivision of Nuclear Medicine, Diagnostic Department, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Pierre Benoit BonnefoyService de Médecine Nucléaire, CHU de Saint-Etienne, Saint-Étienne, France.
Medge CoulangesAdvanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Jun TangNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Christelle SeigneNovartis Pharma AG, Basel, Switzerland; and.
Celine WilkeNovartis Pharma AG, Basel, Switzerland; and.
Ana M CatafauAdvanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Andrei IagaruStanford University, Stanford, California.
Rahul AggarwalUniversity of California San Francisco, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improved diagnostic accuracy in patients with prostate cancer at first biochemical recurrence (BCR) with low prostate-specific antigen (PSA) levels is needed. This prospective study (GuidePath; NCT04838613) aimed to evaluate the imaging performance of the prostate-specific membrane antigen (PSMA)-targeted PET radiotracer [

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedFluorine RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedProspective StudiesRecurrenceFluorine RadioisotopesGlutamate Carboxypeptidase II[18F]CTT1057biochemical recurrenceclinical trialPETprostate-specific membrane antigen

Identifiers

PMID40473464
PMCPMC12320562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.